Optimism Fuels First-of-Its-Kind Glioblastoma Trial Combining Immunotherapy and Electric Field Therapy
A clinical trial underway in California offers a beacon of hope for patients battling glioblastoma (GBM), a particularly aggressive and deadly form of brain cancer, thanks to the pioneering spirit of one patient, Kayvon Goodarzy. Despite decades of research yielding limited progress, a novel approach combining natural killer (NK) cell immunotherapy with the Optune Gio device is showing promising results and prompting an expansion of the clinical study at Hoag Hospital in Newport Beach.
The Challenge of Glioblastoma
For years, the standard of care for GBM has revolved around chemotherapy and radiation, often with less-than-ideal outcomes. The lack of new, approved therapies has left patients and their families disheartened. “The standard of care…has seen only incremental improvement,” one patient shared, reflecting the frustration felt by many facing this diagnosis. Kayvon’s journey began in 2024, when he reluctantly took medical leave from his demanding banking career due to the debilitating fatigue caused by the tumor.
A Novel Combination Therapy
Kayvon is the first person globally to undergo NK cell immunotherapy in conjunction with the Optune Gio device as part of a clinical trial. The Optune Gio is an electric field-generating device worn on the scalp, emitting an electromagnetic field designed to disrupt cancer cell division. This innovative pairing has yielded such positive initial results that Hoag is now launching an extension of its phase 2, randomized clinical trial. The goal is to determine if this approach can become a new standard of care for this rare, yet invariably fatal, cancer.
The treatment involves utilizing special NK cells, enhanced with a lab-made protein called N803, to bolster the body’s immune response, alongside the existing drug bevacizumab. These therapies are designed to “wake up” the immune system and empower it to fight cancer more effectively. Kayvon expressed excitement about harnessing his immune system, rather than suppressing it, and was intrigued by the mechanism of the NK cells.
Breaking Barriers in Treatment Delivery
A key advantage of using NK cells lies in their ability to cross the blood-brain barrier, allowing for intravenous administration without the need for invasive surgical procedures. Traditionally, other cell therapies require a port in the scalp, which would preclude the use of the Optune Gio device. However, Kayvon’s willingness to combine these therapies – and his unique response – appears to have unlocked a significant breakthrough.
According to researchers, the Optune device seems to have altered the environment around the tumor, enhancing the effectiveness of both the NK cells and the N803 protein. Following his positive response, Hoag initiated the trial extension to assess whether these results can be replicated in a larger patient population.
The Trial’s Next Phase
The extension study will randomize participants into two groups. One cohort will receive the NK cells/N803 injection/bevacizumab infusion in combination with Optune, while the other will receive all components except the NK cells. This rigorous design will help determine the specific contribution of each element to the observed benefits.
“Our hope is that this becomes the standard treatment that you can get from the very beginning,” Kayvon stated, expressing his optimism that his experience could revolutionize GBM treatment worldwide.
Hoag’s Commitment to Neuro-Oncology and Community Health
The clinical trial is being led by Simon Khagi, MD, medical director of neuro-oncology at Hoag Family Cancer Institute. Hoag, a nonprofit regional health care network in Orange County, California, serves over 30,000 inpatients and 480,000 outpatients annually. The institution has invested $261 million in community programs over the past five years, focusing on areas like mental health and support for vulnerable populations. Hoag is also recognized as a Magnet® hospital by the American Nurses Credentialing Center (ANCC) and consistently ranks among the top hospitals in California, according to U.S. News & World Report.
